Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 5/2019

Open Access 01-05-2019 | Original Research Article

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus

Authors: Hanne Haahr, Thomas R. Pieber, Chantal Mathieu, Theis Gondolf, Masanari Shiramoto, Lars Erichsen, Tim Heise

Published in: Clinical Pharmacokinetics | Issue 5/2019

Login to get access

Abstract

Background

Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp). This post hoc analysis investigated the pharmacokinetics of faster aspart versus IAsp, measured as free or total IAsp, and the relationship between anti-IAsp antibodies and the pharmacokinetics/pharmacodynamics of faster aspart and IAsp.

Methods

Free and total IAsp concentrations and anti-IAsp antibodies were determined in adults with type 1 diabetes mellitus receiving subcutaneous faster aspart and/or IAsp in four single-dose clinical pharmacology trials (n = 175) and a 26-week phase IIIa trial (n = 1040). Pharmacodynamics were assessed by euglycaemic clamp or meal test, respectively.

Results

The pharmacokinetic profile was left-shifted and early exposure was greater with faster aspart versus IAsp independent of free or total IAsp assay. The faster aspart-IAsp difference in the time to 50% of maximum IAsp concentration in the early part of the pharmacokinetic profile (tEarly 50 % Cmax) [95% confidence interval (CI)] was − 8.8 [− 10.0 to − 7.5] and − 7.6 [− 8.8 to − 6.4] min for free and total IAsp, respectively. The faster aspart/IAsp ratio for the area under the concentration–time curve (AUC) for IAsp from time zero to 30 min (AUCIAsp,0–30 min) [95% CI] was 1.88 [1.74–2.04] and 1.77 [1.64–1.90] for free and total IAsp. Higher anti-IAsp antibody levels were associated with a lower ratio of free/total IAsp for the total AUC for IAsp (AUCIAsp,0–t). Early glucose-lowering effect (AUC for the glucose infusion rate [GIR] from time zero to 60 min [AUCGIR,0–60 min]) was greater by 25–44% for faster aspart versus IAsp independent of anti-IAsp antibody levels. Total glucose-lowering effect (total AUC for GIR [AUCGIR,0–t]) in a clamp and 1-h postprandial glucose increment in a meal test appeared essentially unaffected by anti-IAsp antibodies.

Conclusions

Faster aspart provides accelerated pharmacokinetics versus IAsp regardless if based on free or total IAsp assay. Higher anti-IAsp antibodies increase total IAsp concentrations but do not influence faster aspart nor IAsp pharmacodynamics.

ClinicalTrials.gov identifiers

NCT01618188, NCT02003677, NCT01934712, NCT02568280, NCT01831765.
Appendix
Available only for authorised users
Literature
1.
Arnqvist H, Olsson PO, von Schenck H. Free and total insulin as determined after precipitation with polyethylene glycol: analytical characteristics and effects of sample handling and storage. Clin Chem. 1987;33:93–6.PubMed
2.
Sapin R. Insulin assays: previously known and new analytical features. Clin Lab. 2003;49:113–21.PubMed
3.
Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care. 1989;12:641–8.CrossRefPubMed
4.
Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev. 2007;28:625–52.CrossRefPubMed
5.
Klingensmith GJ. Insulin antibodies-are they still with us? Do they matter? Pediatr Diabetes. 2011;12:75–7.CrossRefPubMed
6.
Sapin R. Anti-insulin antibodies in insulin immunometric assays: a still possible pitfall. Eur J Clin Chem Clin Biochem. 1997;35:365–7.PubMed
7.
Biester T, Danne T, Bläsig S, et al. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes. Pediatr Diabetes. 2016;17:642–9.CrossRefPubMed
8.
Lamos EM, Younk LM, Tate DB, Davis SN. Pharmacokinetics and pharmacodynamics of insulin glargine-insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals. J Clin Transl Endocrinol. 2015;3:14–20.PubMedPubMedCentral
9.
Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care. 2005;28:2100–5.CrossRefPubMed
10.
de la Peña A, Seger M, Soon D, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharmacol Drug Dev. 2016;5:69–75.CrossRefPubMed
11.
12.
13.
14.
Buckley ST, Kildegaard J, Høiberg-Nielsen R, et al. Mechanistic analysis into the mode(s) of action of niacinamide in faster-acting insulin aspart. Diabetes Technol Ther. 2016;18(Suppl 1):A116–7.
15.
Heise T, Hövelmann U, Brøndsted L, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682–8.CrossRefPubMedPubMedCentral
16.
Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017;56:551–9.CrossRefPubMedPubMedCentral
17.
Heise T, Hövelmann U, Zijlstra E, et al. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. Drugs Aging. 2017;34:29–38.CrossRefPubMed
18.
Shiramoto M, Nishida T, Hansen AK, Haahr H. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart. J Diabetes Investig. 2018;9:303–10.CrossRefPubMed
19.
Basu A, Pieber TR, Hansen AK, et al. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. Diabetes Obes Metab. 2018;20:1615–22.CrossRefPubMedPubMedCentral
20.
Russell-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (Onset 1). Diabetes Care. 2017;40:943–50.CrossRefPubMed
21.
Kurtz AB, Mustaffa BE, Daggett PR, Nabarro JD. Effect of insulin antibodies on free and total plasma-insulin. Lancet. 1977;2:56–8.CrossRefPubMed
22.
Waldhäusl WK, Bratusch-Marrain P, Kruse V, Jensen I, Nowotny P, Vierhapper H. Effect of insulin antibodies on insulin pharmacokinetics and glucose utilization in insulin-dependent diabetic patients. Diabetes. 1985;34:166–73.CrossRefPubMed
23.
Hübinger A, Becker A, Gries FA. Total insulin levels in type 1 diabetic patients with insulin antibodies and their effect on insulin requirement and metabolic control. Diabetes Res. 1988;7:65–9.PubMed
24.
25.
Faix JD. Principles and pitfalls of free hormone measurements. Best Pract Res Clin Endocrinol Metab. 2013;27:631–45.CrossRefPubMed
26.
Van Haeften TW, Bolli GB, Dimitriadis GD, Gottesman IS, Horwitz DL, Gerich JE. Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus. Metabolism. 1986;35:649–56.CrossRefPubMed
27.
Heise T, Bott S, Tusek C, et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care. 2005;28:2161–9.CrossRefPubMed
28.
Chen JW, Frystyk J, Lauritzen T, Christiansen JS. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes. Eur J Endocrinol. 2005;153:907–13.CrossRefPubMed
29.
Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;25:876–82.CrossRefPubMed
30.
Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care. 2004;27:162–7.CrossRefPubMed
31.
Fineberg SE, Kawabata TT, Krasner AS, Fineberg NS. Insulin antibodies with pulmonary delivery of insulin. Diabetes Technol Ther. 2007;9:S102–10.CrossRefPubMed
32.
33.
De Block C, Carlson A, Rose L, Gondolf T, Gorst-Rasmussen A, Lane W. Hypoglycemia with mealtime fast-acting insulin aspart vs. insulin aspart across two large type 1 diabetes trials [poster no. 96-LB]. American Diabetes Association, 78th Scientific Sessions; 22–26 Jun 2018; Orlando.
Metadata
Title
Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
Authors
Hanne Haahr
Thomas R. Pieber
Chantal Mathieu
Theis Gondolf
Masanari Shiramoto
Lars Erichsen
Tim Heise
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 5/2019
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0718-6

Other articles of this Issue 5/2019

Clinical Pharmacokinetics 5/2019 Go to the issue

Review Article

Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation

Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development

Original Research Article

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Review Article

Cardiovascular Risk Management and Hepatitis C: Combining Drugs

Original Research Article

Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients

Original Research Article

Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies